Abstracts Archive - Page 322 of 2425 - ACR Meeting Abstracts

Abstract Number: 1412 • ACR Convergence 2023
Improvements in Patient-Reported Outcomes Through 6 Months of Guselkumab Treatment in Patients with Active Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J. Mease¹, Alexis R Ogdie², John Tesser³, Natalie shiff⁴, Iris Lin⁵, Soumya Chakravarty⁶, Mike Kelleman⁷, Rhiannon Dodge⁷, Robert McLean⁷, Aaron Broadwell⁸, Arthur Kavanaugh⁹ and Joseph F. Merola¹⁰, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁴Immunology, Janssen Scientific Affairs, LLC / Adjunct, Community Health and Epidemiology, University of Saskatchewan, Horsham, PA, ⁵Janssen, Horsham, PA, ⁶Immunology, Janssen Scientific Affairs, LLC / Division of Rheumatology, Drexel University College of Medicine, Villanova, PA, ⁷CorEvitas, LLC, Waltham, MA, ⁸Department of Rheumatology, Rheumatology and Osteoporosis Specialists, Shreveport, LA, ⁹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ¹⁰Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Guselkumab (GUS) has demonstrated significant efficacy across disease domains in controlled clinical trials of patients (pts) with active PsA.1,2 Recent CorEvitas PsA/SpA Registry analyses…
Abstract Number: 1413 • ACR Convergence 2023
Effect of Apremilast Treatment on the Domains of MDA-Joints in Patients with Early Oligoarticular Psoriatic Arthritis: 16-Week Results from FOREMOST
Philip J. Mease¹, Alexis R Ogdie², Kristina Callis Duffin³, Jyotsna Reddy⁴, Rebecca Wang⁴, Shauna Jardon⁴ and Laura Coates⁵, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³University of Utah, Salt Lake City, UT, ⁴Amgen, Inc., Thousand Oaks, CA, ⁵University of Oxford, Oxford, United Kingdom
Background/Purpose: The modified minimal disease activity (MDA-Joints) is a novel composite endpoint to assess disease activity and treatment effect in PsA based on a criteria…
Abstract Number: 1433 • ACR Convergence 2023
Bimekizumab Impact on Core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Domains for Patients with Psoriatic Arthritis: 52-Week Results from Four Phase 3 Studies
Joseph Merola¹, Philip J. Mease², Atul Deodhar³, Barbara Ink⁴, Carmen Fleurinck⁵, Rajan Bajracharya⁴, Jason Coarse⁶ and Laura Coates⁷, ¹Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ²Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ³Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Oosterzele, Belgium, ⁶UCB Pharma, Morrisville, NC, ⁷University of Oxford, Oxford, United Kingdom
Background/Purpose: The Group for Research and Assessment of Psoriasis and PsA (GRAPPA) domain‑based treatment recommendations for PsA focus on six key domains: peripheral arthritis, axial…
Abstract Number: 1429 • ACR Convergence 2023
Longitudinal Evaluation of the Novel Psoriatic Arthritis 5-Thermometer Scale (PsA-5Ts) Domains During Treatment with Guselkumab: Pooled Analysis of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
Carlo Selmi¹, Fausto Salaffi², Sibel Aydin³, Enrique Soriano⁴, Emmanouil Rampakakis⁵, Mohamed Sharaf⁶, Miriam Zimmermann⁷, Frederic Lavie⁸, Peter Nash⁹ and Philip J. Mease¹⁰, ¹Rheumatology and Clinical Immunology, Humanitas Research Hospital / Internal Medicine, Humanitas University, Rozzano, Italy, ²Polytechnic University of Marche, Department of Clinical and Molecular Sciences, Carlo Urbani Hospital, Ancona, Italy, ³Department of Medicine, Ottawa Hospital Riverside Campus, Ottawa, ON, Canada, ⁴Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁶Immunology, Janssen MEA, Dubai, United Arab Emirates, ⁷Immunology, Janssen Medical Affairs, LLC, Zug, Switzerland, ⁸The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ⁹School of Medicine, Griffith University, Brisbane, Australia, ¹⁰Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: PsA-5Ts is a simple multidimensional composite measure, assessing pain, fatigue, physical function, skin problems, and depression, recently developed to measure overall health in PsA…
Abstract Number: 1376 • ACR Convergence 2023
SJOGRENSER Registry: Prospective Evaluation of a Cohort of Patients with Primary Sjögren’s Syndrome After 8 Years of Follow-up
Mónica Fernández-Castro¹, Zulema Plaza², Jose Rosas³, Victor Martinez-Taboada⁴, Alejandro Olivé⁵, Raúl Menor-Almagro⁶, SARA MANRIQUE⁷, Ruth López-González⁸, Celia Erausquin⁹, Antonio Naranjo⁹, Rocío Caño-Alameda¹⁰, Silvia Gómez-Sabater¹⁰, Jesús Alberto García Vadillo¹¹, Belen Serrano Benavente¹², Sheila Melchor¹³, Paula V. Estrada-Alarcón¹⁴, Angel Garcia-Aparicio¹⁵, Cristina Bohorquez¹⁶, Enrique Júdez¹⁷, Ximena Larco¹⁸, Javier Loricera¹⁹, Nerea Alcorta Lorenzo²⁰, Beatriz Paredes Romero²¹, Jorge González Martín²², María Ángeles Blázquez Cañamero²³, Consuelo Ramos-Giráldez²⁴, Fernando Alonso²⁵, Marta Domínguez²⁶ and Jose Luis Andreu-Sánchez²⁷, ¹Rheumatology Department Hospital Puerta de Hierro Majadahonda, Majadahonda, Spain, ²Universidad Autónoma de Madrid, Madrid, Spain, ³Hospital Marina Baixa, Alicante, Spain, ⁴Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ⁵Rheumatology Department Hospital Germans Trias i Pujol, Badalona, Spain, ⁶Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ⁷Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁸Rheumatology Department Hospital Virgen de la Concha, Zamora, Spain, ⁹Rheumatology Department Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ¹⁰Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, ¹¹Rheumatology Department Hospital de la Princesa, Madrid, Spain, ¹²Rheumatology Department Hospital Gregorio Marañón, Madrid, Spain, ¹³Rheumatology Department Hospital Doce de Octubre, Madrid, Spain, ¹⁴Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ¹⁵Hospital Universitario de Toledo, Toledo, Spain, ¹⁶Rheumatology Unit, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ¹⁷Rheumatology Department Hospital de Albacete, Albacete, Spain, ¹⁸Rheumatology Department Hospital de León, León, Spain, ¹⁹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²⁰University Hospital Donostia, San Sebastian, Spain, ²¹Rheumatology Department Hospital Infanta Sofía, San Sebastian de los Reyes, Spain, ²²Rheumatology Department Hospital Madrid Norte Sanchinarro, Madrid, Spain, ²³Rheumatology Department Hospital Ramon y Cajal, Madrid, Spain, ²⁴Rheumatology Department Hospital Universitario Virgen de Valme, Sevilla, Spain, ²⁵Spanish Society of Rheumatology, Madrid, Spain, ²⁶Sociedad Española de Reumatología, Madrid, Spain, ²⁷Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: Describe the evolution of patients with Sjögren's syndrome (SS) in relation to the appearance of new systemic manifestations and disease activity, as well as…
Abstract Number: 1416 • ACR Convergence 2023
Improvement of Work Absenteeism Following Start of Methotrexate Monotherapy in Newly-Diagnosed Psoriatic Arthritis
Ulf Lindström¹, Daniela Di Giuseppe², Sofia Exarchou³, Gerd-Marie Alenius⁴, Tor Olofsson⁵, Eva Klingberg¹, Lennart Jacobsson⁶, Johan Askling² and Johan Karlsson Wallman⁵, ¹University of Gothenburg, Gothenburg, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Lund University, Åkarp, Sweden, ⁴Umeå University, Umeå, Sweden, ⁵Lund University and Skåne University Hospital, Lund, Sweden, ⁶University of Gothenburg, Malmö, Sweden
Background/Purpose: In many countries, methotrexate (MTX) monotherapy is the first-line disease-modifying anti-rheumatic drug (DMARD) therapy for psoriatic arthritis (PsA), despite that its efficacy in PsA…
Abstract Number: 1428 • ACR Convergence 2023
Guselkumab Provides Clinically Meaningful Improvents in Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Who Are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled Study (COSMOS)
Laure Gossec¹, Xenofon Baraliakos², James Galloway³, Lars Erik⁴, Vilija Oke⁵, Petros Sfikakis⁶, Emmanouil Rampakakis⁷, Mohamed Sharaf⁸, Frederic Lavie⁹ and Iain McInnes¹⁰, ¹Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³King's College London, London, United Kingdom, ⁴Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶National Kapodistrian University of Athens Medical School, Athens, Greece, ⁷JSS Medical Research, Saint-Laurent, QC, Canada, ⁸Immunology, Janssen MEA, Dubai, United Arab Emirates, ⁹The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ¹⁰University of Glasgow, Glasgow, United Kingdom
Background/Purpose: In the Phase 3b COSMOS trial, guselkumab (GUS), a fully human IL-23p19 inhibitor (i), was associated with significantly greater improvements vs placebo (PBO) in…
Abstract Number: 1426 • ACR Convergence 2023
Distinct Treatment Response Trajectories in Patients with Psoriatic Arthritis Receiving Tofacitinib
Dafna Gladman¹, William R Tillett², David Gruben³, Laura Coates⁴, Stefanie Hahne⁵ and Mikhail Volkov⁶, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Pfizer Inc., Groton, CT, ⁴University of Oxford, Oxford, United Kingdom, ⁵Pfizer Pharma GmbH, Berlin, Germany, ⁶Pfizer BV, Capelle aan den IJssel, Netherlands
Background/Purpose: PsA is a heterogeneous disease, and identifying clinical phenotypes may assist clinical decision making. Patients (pts) treated with advanced therapies demonstrate varying treatment responses.…
Abstract Number: 1438 • ACR Convergence 2023
Efficacy of Guselkumab in Early-Onset and Late-Onset Psoriatic Arthritis: Post Hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials in Patients with Active PsA
Enrique Soriano¹, Mitsumasa Kishimoto², Emmanouil Rampakakis³, Francois Nantel⁴, May Shawi⁵, Frederic Lavie⁶, Philip J. Mease⁷ and Dafna Gladman⁸, ¹Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Kyorin University School of Medicine, Yokohoma, Japan, ³McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁴Nantel Medsci Consult, Consultant, Montreal, QC, Canada, ⁵Immunology, Janssen Research & Development, LLC, Titusville, NJ, ⁶The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ⁷Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁸Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Late-onset PsA may be associated with elevated acute phase reactants, higher joint count, and erosive disease at diagnosis1,2. Given potential phenotype differences and increasing…
Abstract Number: 1149 • ACR Convergence 2023
Tumor Necrosis Factor Inhibitors as First Line Steroid-Sparing Therapy for Neurosarcoidosis: A Case Series
Tessalyn Morrison¹, Taylor Lakusta-Wong¹, Chantal Roy-Hewitson¹, Jeanne Gosselin² and Alana Nevares³, ¹University of Vermont, Burlington, VT, ²University of Vermont Medical Center, Waterbury, VT, ³University of Vermont, Essex Junction, VT
Background/Purpose: Sarcoidosis is a systemic inflammatory disease characterized by non-necrotizing granuloma formation affecting the lung, lymphatics, heart, skin, eye, kidney, and, in neurosarcoidosis, the nervous…
Abstract Number: 1397 • ACR Convergence 2023
Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
Victoria Navarro-Compán¹, Lianne Gensler², Martin Rudwaleit³, Fabiana Ganz⁴, Shirley Chen⁴, Jayne Stigler⁴, Anna Schmagel⁴ and Xenofon Baraliakos⁵, ¹Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ³University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁴AbbVie, Inc., North Chicago, IL, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Bochum, Germany
Background/Purpose: Upadacitinib 15 mg (UPA), an oral Janus kinase inhibitor, has shown efficacy and tolerability through 14 weeks in patients (pts) with active radiographic axial…
Abstract Number: 1366 • ACR Convergence 2023
A Unique Cluster of Inflammatory Monocytes and Functionally Intact Regulatory T Cells in Rare Childhood Sjögren’s Disease
Myung-Chul Kim¹, Umasankar De², Nicholas Borcherding³, Joon Paek⁴, Nicole Winn⁵, Indraneel Bhattacharyya⁶, Qing Yu⁷, Ryan Kolb⁸, Theodore Drashansky⁹, Akaluck Thatayatikom¹⁰, Weizhou Zhang⁸ and Seunghee Cha¹¹, ¹Jeju National University, Jeju-si, South Korea, ²University of Florida, Gainesville, FL, ³Washington University School of Medicine in St. Louis, Washington, DC, ⁴Department of Oral & Maxillofacial Diagnostic Sciences, Gainesville, FL, ⁵Division of Oral Medicine, Department of Oral and Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry, Gainesville, FL, ⁶Department of Oral & Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry, Gainesville, FL, ⁷The Forsyth Institute, Cambridge, MA, ⁸Department of Pathology & Immunology, University of Florida, Gainesville, FL, ⁹Cellularity, Inc, Florham Park, NJ, ¹⁰AdventHealth for Children, Orlando, FL, Orlando, FL, ¹¹Department of Oral & Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry and Center for Orphaned Autoimmune Disorders (COAD), Gainesville, FL
Background/Purpose: This study was performed to characterize key immune cell subsets and their interactions in patients with childhood Sjögren's disease (cSjD) for the first time…
Abstract Number: 1403 • ACR Convergence 2023
MRI-defined Sacroiliitis in First Degree Relatives of Ankylosing Spondylitis Patients
Kristyna Bubova¹, Lenka Hasikova², Katerina Mintalova², Monika Gregova², Sarka Forejtova², Ladislav Senolt³ and Karel Pavelka⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic, ⁴Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic
Background/Purpose: Sacroiliitis is a main radiographic finding in axial spondyloarthritis (axSpA) - the inflammatory rheumatic disease with a strong genetic background. The aim of this…
Abstract Number: 1449 • ACR Convergence 2023
Evaluation of Progression from Preclinical to Systemic Autoimmune Rheumatic Disease
Joan Wither¹, Dennisse Bonilla², Zareen Ahmad¹, Arthur Bookman³, Linda Hiraki⁴, Earl Silverman⁵, Mohammad Movahedi¹, Sindhu Johnson⁶ and Hana Salem Alahmari⁷, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Toronto Western Hospital, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Silverman, Toronto, ON, Canada, ⁶Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ⁷Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: To evaluate the development of a systemic autoimmune rheumatic disease (SARD) in undifferentiated and asymptomatic individuals with antinuclear antibodies (ANA). We evaluated fulfillment of…
Abstract Number: 1211 • ACR Convergence 2023
Description of Self-Efficacy for Managing Symptoms and Emotions in a Large Rheumatology Clinic Population
Rachel Dayno¹, Michael George¹, Kimberly DeQuattro², Marissa Blum³, Sharon Kolasinski⁴ and Dana DiRenzo⁵, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Media, PA, ³University of Pennsylvania, Cherry Hill, NJ, ⁴University of Pennsylvania, Philadephia, PA, ⁵University of Pennsylvania, Bala Cynwyd, PA
Background/Purpose: Self-efficacy (SE) is the inner belief in one's ability to succeed in specific situations and tasks. SE for managing the symptoms and emotions associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].